Last reviewed · How we verify
Placebo to match zanamivir — Competitive Intelligence Brief
phase 3
Infectious Disease
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo to match zanamivir (Placebo to match zanamivir) — GlaxoSmithKline. This is an inert placebo formulation designed to match the physical and sensory characteristics of zanamivir for blinded clinical trial comparisons.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo to match zanamivir TARGET | Placebo to match zanamivir | GlaxoSmithKline | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo to match zanamivir CI watch — RSS
- Placebo to match zanamivir CI watch — Atom
- Placebo to match zanamivir CI watch — JSON
- Placebo to match zanamivir alone — RSS
Cite this brief
Drug Landscape (2026). Placebo to match zanamivir — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-to-match-zanamivir. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab